This News From Novo: A Warning for Eli Lilly Shareholders
A GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
Target date funds adjust asset allocations over time toward a chosen retirement year, simplifying diversification and rebalancing for many savers.
19,808 articlesA GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
SoundHound AI reported its sixth consecutive earnings beat as revenue and AI platform demand accelerate. The LivePers...
Canopy Growth sits at the center of sharp investor debate. This article maps three plausible paths for the stock over...
The trillion-dollar club is expanding, and a few ahead-of-the-curve signals can help you spot the next member. This g...
Market pullbacks can feel daunting, but they’re prime opportunities for long-term gains. This guide reveals how to id...
When a space stock climbs in a single session, headlines shout about momentum. This article breaks down why rocket st...
Sofi stocks have shown impressive momentum, but two big risks loom: a concentrated Galileo platform revenue stream an...
The Pentagon says commercial data was used to target U.S. service members, a development that could spur tighter data...
When an institutional investor takes a large position in a biotech stock, it can signal potential credibility or risk...
In a year of AI-driven consolidation, three enterprise software names are walling off attention as potential takeout ...
Insiders are weighing a bold scenario where SpaceX could climb to as much as $10 trillion by 2030, potentially overta...
Urban air mobility could redefine commuting, but investing in Joby Aviation requires weighing regulation, costs, and ...